This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD5 CAR-NK in the treatment of patients with relapsed/refractory T-Cell hematologic malignancies.
Refractory to ≥2 cycles of standard induction chemotherapy (failure to achieve CR).
Relapsed within 12 months after achieving CR with first-line induction therapy.
Failure to achieve CR or relapse after ≥2 lines of chemotherapy.
Relapse after hematopoietic stem cell transplantation (HSCT).
Prior CAR-NK therapy or genetically modified cell therapy.
Active CNS involvement at screening (prior CNS involvement with resolved status post-treatment is allowed).
Chemotherapy, targeted therapy, or investigational drugs within 2 weeks or 5 half-lives prior to screening.
Radiotherapy within 2 weeks prior to screening.